CNTG (CENTOGENE N.V.) Enterprise Value-to-Revenue Coefficient

Centogene N.V. relies on inelastic demand in genetics and a global biobank. This attracts leading bioinformaticians, as evidenced by the EV/Sales history. The current value of characterizes this valuation metric. A proprietary database of rare mutations creates an insurmountable barrier for competitors, providing pharma behemoths with a reliable analytical foundation for their research.
CNTG (Centogene): analytical breakdowns and indicator data

For Centogene N.V. (CNTG), the EV/Sales chart reflects the enterprise value of the business relative to sales volumes, which is critical when assessing the scaling of its genetic data AI platform. The trend of this indicator allows for a correlation between the issuer's capital value and revenue from contracts with pharma behemoths, determining the extent of asset overvaluation or undervaluation in the context of rising IT test margins.